Vimarsana
Biggest News Aggregation in the World

Page 4 - Ophthalmic Solution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ophthalmic Solution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ophthalmic Solution Today - Breaking & Trending Today

Lupin : August 16, 2023 Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.09% - Vimarsana News

Lupin : August 16, 2023 Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.09%

Mumbai, Baltimore, August 16, 2023: Global pharma major Lupin Limited today announced that it has received approval from the United States Food and Drug Administration for its... -Today at 05:33 am- MarketScreener

Lupin gets USFDA nod for Bromfenac Ophthalmic Solution - Vimarsana News

Lupin gets USFDA nod for Bromfenac Ophthalmic Solution

Pharma major Lupin on Wednesday said it has received approval from the US health regulator to market its generic Bromfenac Ophthalmic Solution used to treat post-operative inflammation in patients who have undergone cataract surgery. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Bromfenac Ophthalmic Solution 0.09 per cent, Lupin said in a regulatory filing.

Why Aldeyra Therapeutics Stock Is Trading Higher Today - Vimarsana News

Why Aldeyra Therapeutics Stock Is Trading Higher Today

Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline results from the Phase 3 INVIGORATE-2 trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis. The trial achieved statistical significance for the primary endpoint and all secondary endpoints. Also Read: Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients. Relative to patients treated with vehicle, patients treated with reproxalap reported statistica

Source: yahoo.com
Akorn Recalls Various Drug Products Due to Company Shutdown - Vimarsana News

Akorn Recalls Various Drug Products Due to Company Shutdown

Akorn has initiated a voluntary recall of various within-expiry drug products as the company has shut down operations.

Akorn Recalls Various Drug Products Due to Company Shutdown - Vimarsana News

Akorn Recalls Various Drug Products Due to Company Shutdown

Akorn has initiated a voluntary recall of various within-expiry drug products due to a company shutdown.